Journal
CELL BIOLOGY INTERNATIONAL
Volume 45, Issue 12, Pages 2420-2428Publisher
WILEY
DOI: 10.1002/cbin.11684
Keywords
colon cancer; drug resistance; erianin; oxaliplatin; P-gp; STAT3
Categories
Funding
- Shanghai Municipal Health Commission [201840138]
Ask authors/readers for more resources
Erianin significantly inhibits the proliferation of human colon cancer oxaliplatin-resistant cells and suppresses the cell cycle of these cells in the G2/M phase, indicating its potential to regulate MDR phenotype through the inhibition of STAT3 signaling pathway and reduction of P-gp expression. This study provides a theoretical basis for the clinical application of erianin in platinum-based chemotherapy for colon cancer.
Multidrug resistance (MDR) is the main cause of chemotherapy failure in the treatment of colon cancer and the high expression of drug efflux protein P-gp is one of the main factors of MDR. P-gp expression is regulated by the signal transducer and activator of transcription 3 (STAT3) signaling pathway. In this study, human colon cancer oxaliplatin-resistant cells were treated with oxaliplatin combined with the natural product erianin. Then, we evaluated the impact of erianin on drug resistance, and explored the relationship between erianin-related oxaliplatin resistance and the Janus kinase 2/STAT3 signaling pathway in vitro. Our research showed that erianin could significantly inhibit the proliferation of human colon cancer oxaliplatin-resistant cells, and suppress the cell cycle of oxaliplatin-resistant cells in the G2/M phase, indicating that erianin could regulate the MDR phenotype of oxaliplatin-resistant cells, and its mechanism might be the inhibition of STAT3 signaling pathway and the significant reduction of P-gp expression. However, this study provides a theoretical basis for the clinical application of erianin in platinum-based chemotherapy for colon cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available